Taltz® ▼ (ixekizumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Taltz Summary of Product Characteristics (SmPC)

Taltz® ▼ (ixekizumab): Dosage Regimen for Psoriatic Arthritis

160 mg at week 0, then 80 mg every 4 weeks.

Dosage Regimen for Psoriatic Arthritis

The recommended dose is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg (one injection) every 4 weeks thereafter.1

For psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis, the recommended dosing regimen is the same as for plaque psoriasis.1

Discontinuation of treatment

Consideration should be given to discontinuing treatment in patients who have shown no response after 16 to 20 weeks of treatment. Some patients with initially partial response may subsequently improve with continued treatment beyond 20 weeks.1

Dosing in specific patient populations

In elderly patients (≥ 65 years) is no dose adjustment required. There is limited information in subjects aged ≥ 75 years.1

Ixekizumab has not been studied in patients with renal or hepatic impairment. No dose recommendations can be made.1

Therapeutic Indication

Ixekizumab, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.1

Ixekizumab is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Ixekizumab is indicated.1

References

1. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

cDMARD = conventional disease-modifying antirheumatic drug

HIV = human immunodeficiency virus

MTX = methotrexate

NSAID = nonsteroidal anti-inflammatory drug

PsA = psoriatic arthritis

Q2W = every 2 weeks

Q4W = every 4 weeks

SC = subcutaneous

TB = tuberculosis

TNF = tumor necrosis factor

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: June 05, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question